JP2014509305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509305A5 JP2014509305A5 JP2013546406A JP2013546406A JP2014509305A5 JP 2014509305 A5 JP2014509305 A5 JP 2014509305A5 JP 2013546406 A JP2013546406 A JP 2013546406A JP 2013546406 A JP2013546406 A JP 2013546406A JP 2014509305 A5 JP2014509305 A5 JP 2014509305A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- subject
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 9
- 238000008214 LDL Cholesterol Methods 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- 102000018616 Apolipoproteins B Human genes 0.000 claims 1
- 108010027006 Apolipoproteins B Proteins 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061427236P | 2010-12-27 | 2010-12-27 | |
| US61/427,236 | 2010-12-27 | ||
| PCT/US2011/066736 WO2012092103A1 (en) | 2010-12-27 | 2011-12-22 | Gemcabene and derivatives for treating pancreatitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178843A Division JP6207560B2 (ja) | 2010-12-27 | 2015-09-10 | 膵炎を治療するためのゲムカベンおよび誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509305A JP2014509305A (ja) | 2014-04-17 |
| JP2014509305A5 true JP2014509305A5 (enExample) | 2015-02-12 |
Family
ID=45498140
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546406A Withdrawn JP2014509305A (ja) | 2010-12-27 | 2011-12-22 | 膵炎を治療するためのゲムカベンおよび誘導体 |
| JP2015178843A Active JP6207560B2 (ja) | 2010-12-27 | 2015-09-10 | 膵炎を治療するためのゲムカベンおよび誘導体 |
| JP2017169145A Pending JP2018027953A (ja) | 2010-12-27 | 2017-09-04 | 膵炎を治療するためのゲムカベンおよび誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178843A Active JP6207560B2 (ja) | 2010-12-27 | 2015-09-10 | 膵炎を治療するためのゲムカベンおよび誘導体 |
| JP2017169145A Pending JP2018027953A (ja) | 2010-12-27 | 2017-09-04 | 膵炎を治療するためのゲムカベンおよび誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8846761B2 (enExample) |
| EP (2) | EP2658536B1 (enExample) |
| JP (3) | JP2014509305A (enExample) |
| CN (2) | CN107648210A (enExample) |
| AU (1) | AU2011352449B2 (enExample) |
| CA (1) | CA2822921C (enExample) |
| DK (1) | DK2658536T3 (enExample) |
| ES (1) | ES2608177T3 (enExample) |
| HK (1) | HK1250484A1 (enExample) |
| HU (1) | HUE031004T2 (enExample) |
| MX (1) | MX337593B (enExample) |
| PL (1) | PL2658536T3 (enExample) |
| PT (1) | PT2658536T (enExample) |
| WO (1) | WO2012092103A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201702496XA (en) | 2014-11-14 | 2017-04-27 | Gemphire Therapeutics Inc | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| JP2018536710A (ja) * | 2015-11-06 | 2018-12-13 | ジェンファイア・セラピューティクス・インコーポレイテッドＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 混合型脂質異常症の治療 |
| JP2020516622A (ja) | 2017-04-18 | 2020-06-11 | ジェムフィアー セラピューティクス インコーポレイテッド | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR900701262A (ko) * | 1988-06-06 | 1990-12-01 | 오까모도 쇼오스께 | 췌장염 등에 대한 치료제 |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| US20020103252A1 (en) | 1997-12-12 | 2002-08-01 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| US20030105154A1 (en) * | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| JP2002541129A (ja) | 1999-04-01 | 2002-12-03 | エスペリオン セラピューティクス インコーポレイテッド | エーテル化合物、組成物、およびそれらの使用 |
| US6713507B2 (en) * | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| US6645170B2 (en) | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
| US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
| US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
-
2011
- 2011-12-22 CN CN201710858297.9A patent/CN107648210A/zh active Pending
- 2011-12-22 HU HUE11810759A patent/HUE031004T2/en unknown
- 2011-12-22 MX MX2013007310A patent/MX337593B/es active IP Right Grant
- 2011-12-22 WO PCT/US2011/066736 patent/WO2012092103A1/en not_active Ceased
- 2011-12-22 CN CN2011800630388A patent/CN103442707A/zh active Pending
- 2011-12-22 AU AU2011352449A patent/AU2011352449B2/en not_active Ceased
- 2011-12-22 ES ES11810759.8T patent/ES2608177T3/es active Active
- 2011-12-22 JP JP2013546406A patent/JP2014509305A/ja not_active Withdrawn
- 2011-12-22 PL PL11810759T patent/PL2658536T3/pl unknown
- 2011-12-22 DK DK11810759.8T patent/DK2658536T3/en active
- 2011-12-22 CA CA2822921A patent/CA2822921C/en active Active
- 2011-12-22 US US13/334,384 patent/US8846761B2/en active Active
- 2011-12-22 PT PT118107598T patent/PT2658536T/pt unknown
- 2011-12-22 EP EP11810759.8A patent/EP2658536B1/en active Active
- 2011-12-22 EP EP16192597.9A patent/EP3170495B1/en active Active
-
2015
- 2015-09-10 JP JP2015178843A patent/JP6207560B2/ja active Active
-
2017
- 2017-09-04 JP JP2017169145A patent/JP2018027953A/ja active Pending
-
2018
- 2018-08-01 HK HK18109899.3A patent/HK1250484A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2861643C (en) | Methods of reducing risk of cardiovascular disease | |
| JP2010077141A5 (enExample) | ||
| JP2017505285A5 (enExample) | ||
| JP2012097105A5 (enExample) | ||
| JP2017513836A5 (enExample) | ||
| JP2013500986A5 (enExample) | ||
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2009530398A5 (enExample) | ||
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| JP2013542247A5 (enExample) | ||
| NZ743706A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| JP2017508817A5 (enExample) | ||
| JP2014505017A5 (enExample) | ||
| JP2015509075A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| JP2014515407A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| JP2014521641A5 (enExample) | ||
| JP2013513607A5 (enExample) | ||
| JP2012505905A5 (enExample) | ||
| JP2014509305A5 (enExample) | ||
| RU2010138650A (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| JP2019516726A5 (enExample) |